Abivax (AAVXF) Cash from Operations (2024 - 2026)

Abivax has reported Cash from Operations for 3 years, with the latest figure at -$59.1 million in Q1 2026.

• On a quarterly basis, Cash from Operations fell 68.96% year-over-year to -$59.1 million in Q1 2026; TTM through Mar 2026 was -$187.6 billion, a 13.93% decrease from a year earlier, with the FY2025 full-year figure at -$187.6 billion, down 13.92% from the prior year.
• Cash from Operations was -$59.1 million for Q1 2026 at Abivax, up from -$187.4 billion in the prior quarter.
• The five-year high for Cash from Operations was -$35.0 million in Q1 2025, with the low at -$187.4 billion in Q4 2025.
• Average Cash from Operations over 3 years is -$39.1 billion, with a median of -$54.3 million recorded in 2024.
• The largest YoY upside for Cash from Operations was 30.5% in 2025 against a maximum downside of 114.46% in 2025.
• Over 3 years, Cash from Operations stood at -$164.5 billion in 2024, then decreased by 13.91% to -$187.4 billion in 2025, then soared by 99.97% to -$59.1 million in 2026.
• The last three Cash from Operations figures came in at -$59.1 million (Q1 2026), -$187.4 billion (Q4 2025), and -$83.3 million (Q3 2025), per Business Quant data.